What are the subgroups for clinical trials in ROC? The historical definition of using platinum-free interval (PFI) to categorise patients as having platinum-sensitive/resistant disease was replaced by therapy-free interval (TFI). TFI can be broken down into TFIp (PFI), TFInp (non-PFI) and TFIb (biological agent-free interval). Additional criteria to consider include histology, BRCA mutation status, number/type of previous therapies, outcome of prior surgery and patient reported symptoms. (ii) What are the control arms for clinical trials in ROC? When platinum is considered the best option, the control arm should be a platinum-based therapy with or without an anti-angiogenic agent or a poly (ADP-ribose) polymerase (PARP) inhibitor. If platinum is not considered the best option, the control arm could include a non-platinum drug, either as single agent or in combination. (iii) What are the endpoints for clinical trials in ROC? Overall survival (OS) is the preferred endpoint for patient cohorts with an expected median OS < or ¼ 12 months. Progression-free survival (PFS) is an alternative, and it is the preferred endpoint when the expected median OS is > 12 months. However, PFS alone should not be the only endpoint and must be supported by additional endpoints including pre-defined patient reported outcomes (PROs), time to second subsequent therapy (TSST), or time until definitive deterioration of quality of life (TUDD).
Introduction
At the fifth Ovarian Cancer Consensus Conference (OCCC) of the Gynecologic Cancer InterGroup (GCIG) held in Tokyo, Japan, in November 2015, representatives of 29 international cooperative clinical trial groups in gynaecology oncology gathered to reach consensus on pre-defined questions considered critical to the conduct of randomised trials [1] . Group D, one of the four groups, focussed specifically on recurrent ovarian cancer (ROC)
D1: what are the subgroups for clinical trials in ROC? (Table 1) Defining patient cohorts for inclusion in trials is central to their design, interpretation and ultimate success. A key objective of this consensus meeting was to define specific patient subgroups for inclusion in clinical trials in ROC. The platinum-free interval (PFI), defined as the interval between the date of the last platinum dose and the date of relapse, has been the most widely used and accepted clinical surrogate for predicting chemotherapy response, prognosis as well as selection and stratification of patient cohorts in trials [2] . However, there was general consensus that the varying frequencies and types of investigations (CA-125, CTor PET-scan and/or clinical) during follow-up influence the time at which relapse is diagnosed. This significantly impacts categorisation of patients as 'platinum sensitive' or 'platinum resistant'.
At the fourth OCCC in Vancouver in 2010, the first step was initiated towards disconnecting PFI length from the notion of platinum-sensitivity or resistance [1, 2] . It was recognised that response rates to platinum fall on a continuum, and agreement was reached that patients entered into clinical trials should be categorised into four subsets based on PFI duration (<1 month, 1-6 months, 6-12 months, and >12 months). These subgroups corresponded to the widely used categories of platinumrefractory, platinum-resistant, partially platinum-sensitive and fully platinum-sensitive and were an attempt to avoid a value judgment on whether patients will or will not respond to platinum-based therapy. At the fifth OCCC, it was agreed that the time from last platinum remains an integral measure for defining patient populations and predicting outcomes. To overcome the limitations imposed by the arbitrary division of platinum-sensitive and resistant disease, it was agreed that we should report the specific time from the last platinum dose to define the trial population. If time without platinum is used to stratify patients within a trial, the method of diagnosing recurrence should be specified.
With increasing use of non-platinum and biological agents such as PARP inhibitors, angiogenesis inhibitors and immune checkpoint blockade in ROC, clinical trial design needs to collect information evaluating the impact of these agents on disease biology and response to subsequent treatment. It was proposed that PFI, which focuses on only one therapeutic class (platinum), should be replaced with the broader term of treatment-free interval (TFI). In addition to the TFI from last platinum dose (TFIp), the TFI from last non-platinum therapy (TFInp) as well as last biological agent (TFIb), when applicable, should be recorded prospectively. For example, if a patient received maintenance bevacizumab and completed this therapy 3 months before progression, this should be recorded as a TFIbev of 3 months. Furthermore, the data collected must be clinically relevant to the patient population. In surgical trials, integrating TFI from last cytoreductive surgery may be more relevant to stratification than time from last systemic therapy.
The paradigm of simply categorising patients with ROC according to TFIp, which is linked to chemotherapy sensitivity, may evolve in the future as we enter the targeted therapy era. Predictive biomarkers for response to targeted therapies are expected to be more important than TFIp with respect to predicting benefit, particularly when chemotherapy is not used. Even though a predictive biomarker for the success of treatment with bevacizumab (a monoclonal anti-body directed against vascular endothelial growth factor (VEGF)) remains elusive, the clinical benefit of using bevacizumab in conjunction with chemotherapy in ROC seems independent of TFIp [3, 4] . Furthermore, olaparib (a PARP inhibitor) appears especially active in tumours deficient in the homologous recombination DNA repair pathway (HRD) and particularly in those tumours with a germ-line or somatic BRCA mutation, which currently serves as a predictive biomarker. This DNA repair deficiency also confers a unique sensitivity to platinum, suggesting a link between platinum and PARP inhibitor sensitivity [5] . BRCA, however, is a good example of how a biomarker can define a population of patients with ROC who are more likely to benefit from a targeted treatment (a PARP inhibitor), and where benefit is not related to the TFIp alone. Illustrating this point, olaparib approval in the EU is limited to BRCA mutated patients with a TFIp over 6 months, whereas in the US, olaparib is approved in BRCA mutated patients with heavily pre-treated disease, independent of 'platinumsensitivity'.
Currently, the germ-line BRCA mutation test is the only validated genomic test that should be incorporated in trials in ROC [6, 7] . While response rates and PFS with PARP inhibitors have been well-defined in patients with BRCA mutations [17] [18] [19] , more novel tests including HRD and loss of heterozygosity scores are still under investigation [8] [9] [10] . These novel predictive biomarkers and others (such as p53 and cyclin E) may become an integral part of future trial design but require further validation.
Other important stratification criteria to be considered include histological sub-type. In addition, type/number of prior lines of chemotherapy, outcome of previous surgery and presence and type of symptoms at relapse need consideration.
Epithelial ovarian cancer includes five different molecular subtypes with variable prognosis and response to chemotherapy [11] [12] [13] . Trials serving specific histological sub-types are a priority in first-line as well as recurrent disease; however, these trials present significant challenges, particularly in rarer sub-types, with international collaboration being essential.
Type and outcome of prior therapy is an important consideration, particularly given the changing landscape in clinical practice. Relatively little is known about how maintenance therapy with biological agents impacts subsequent chemotherapy response and outcomes. Retrospective series have suggested no apparent detrimental impact on platinum response following PARP inhibition, but more data are needed [14] . Incorporating TFIs will allow us to collect all information regarding prior treatments in patients recruited to clinical trials, and it will help us assess whether these agents impact response and toxicity experienced with subsequent chemotherapy. The presence and type of symptoms at relapse such as ascites, abdominal symptoms, performance status and pain are also important to patient stratification [15] [16] [17] . These may define patient cohorts with different outcomes as well as those which require specific PRO assessments to determine therapeutic benefit. The nature and severity of symptoms may indicate a need for urgent therapy and prioritise the use of one agent over another. For example, the addition of bevacizumab to chemotherapy has reproducibly provided 20% higher response rates over chemotherapy alone and is particularly active in symptomatic patients with ascites [3, 4, 18] . Conversely, a history of prior bowel obstruction is an important consideration in studies investigating agents targeting VEGF and oral therapies.
The number of prior chemotherapy lines impacts the likelihood of response to further treatments and is often an eligibility criterion [15, 17] . With a rapidly expanding number of treatment options, patients with ROC are receiving an increasing number of lines of therapies. However, current trials in relapse do not reflect this trend, with most studies focusing on patients receiving second and third-line chemotherapy. Patients with multiple prior lines of chemotherapy were identified as having an unmet need, emphasising the need for trials beyond the third-line setting.
It was agreed that details of tumour volume and previous surgical outcomes, such as the volume of residual disease after surgery for recurrent disease, should be collected prospectively as these may be of prognostic importance as more data emerge.
Finally, the question of how age and frailty impact treatment decisions in ROC needs to be addressed. Elderly patients who are considered fit for therapy should be included in standard trials if they meet eligibility criteria. Retrospective data and cohort studies have demonstrated similar benefit of chemotherapy in elderly patients included in trials when compared with those younger [19, 20] . Illustrating this, elderly patients (defined as 70 years) treated with carboplatin/paclitaxel and carboplatin/pegylated liposomal doxorubicin demonstrated similar disease control to younger patients, albeit with different non-haematological toxicities, including fewer allergic reactions, but more neuropathy [21] . Specific trials for elderly or frail patients were recognised as an important unmet need. More efforts should be devoted to developing validated criteria for defining frailty in patients with ROC, age being one component, together with comorbidities and autonomy capacity.
D2: what are the control arms for clinical trials in ROC? (Table 2) As clinical practice evolves, the control arms in clinical trials need to reflect the best-evidence based treatment of the patient population under investigation. Platinum remains the mainstay of treatment at relapse. In the absence of specific biomarkers for platinum resistance, there is still debate over when to offer platinum. At the fourth OCCC it was acknowledged that patients with a TFIp >12 months were the best candidates for treatment with a platinum-based combination [1, 2] . It is assumed that shorter TFIp are associated with worse outcomes when patients are re-challenged with platinum. However, in patients with a short TFIp, low response rates are not specific to platinum but apply to all chemotherapy drugs. Given these considerations, it is recommended that platinum should remain a key component of treatment options at relapse.
Three potential control arms were identified for this patient cohort, dependent on several factors including previous therapy (e.g. bevacizumab), number of prior lines, BRCA mutation (e.g. olaparib), geography (drug available and reimbursed) and drug contra-indications:
(i) platinum combination (ii) platinum combination with a licensed anti-angiogenic agent [3] (iii) platinum combination followed by a licensed PARP inhibitor [9, 10] .
In patients where platinum therapy is not considered a good option, non-platinum based therapy should be the control arm, either as monotherapy or in combination. This may include a group of patients who have responded to platinum treatment but have a short TFIp (the definition of which may vary according to trial criteria but at a minimum<6 months) based on symptomatic or RECIST progression (response evaluation criteria in solid tumours), or who progressed during chemotherapy, or those with a significant platinum allergy. In patients who progressed on chemotherapy or in those with a short TFIp, randomised trials have failed to demonstrate a benefit of combination with non-platinum agents over single agent therapy [22] or substitution of a non-platinum agent with carboplatin as part of combination therapy [23] . However, in patients with a short TFIp, non-platinum therapy combined with a biologic agent such as bevacizumab has demonstrated a significant benefit, particularly for patients with ascites or symptoms [4] . In patients unable to receive platinum with a longer TFIp, combination therapy may include doublet chemotherapy with non-platinum agents [24] .
There is a subgroup of medically compromised patients including, but not limited to, elderly patients, for whom less toxic therapy or best supportive care may be an appropriate control arm. Comorbidities are more likely to hinder tolerance than age alone and are key exclusion criteria in trials. The definition of less toxic therapy was controversial and was supported by all cooperative groups except one (minority statement). This was intended to represent more tolerable cytotoxic regimens such as single agent platinum, combination therapy with decreased dose (compared to standard) or biologic agents as clinical and safety data emerge. Integration of models and scores to better delineate these patient groups will allow prospective data collection.
In line with the fourth OCCC statements, trials for patients with asymptomatic rise in CA-125 were recognised as a challenge [2] . The current standard of care is observation in this population with no proven effective therapy and no evidence of a survival benefit with early initiation of chemotherapy [25] . Consequently, observation or placebo may represent an appropriate control arm but may add an additional barrier to trial accrual. Other options including tamoxifen were discussed, but given very limited evidence without clear benefit, the consensus concluded that no current recommendation for treatment could be made [26] .
Acceptable alternatives for control arms may emerge as new evidence matures. At least one clinical trial demonstrating noninferiority or superiority to the above regimens would be necessary to be considered an appropriate control arm. Extrapolation of data from sub-group analyses should be avoided in defining control arms. The regimens need to reflect the geographical variability in approvals and access in order to improve trial availability at an international level [27, 28] . Legal and economical restrictions need consideration when designing a trial with respect to generalisability and access at an international level.
D3: what are the endpoints for clinical trials in ROC? (Table 3) As specified in the fourth OCCC consensus statements, the endpoints need to demonstrate whether the treatment results in clinical benefit [2] . With the median OS increasing in ROC, demonstrating an OS benefit in trials is becoming increasingly difficult as many patients enjoy long post-progression survival due to post-progression therapies, cross-over to the investigational treatment and improved supportive care [29] [30] [31] [32] [33] . Analyses and statistical models have demonstrated that in cancers with longer post-progression survival, a more divergent relationship is expected between PFS and OS [29, 30] . This requires a large sample size to detect an OS benefit which is beyond most of the current trials in ROC.
A patient on a control arm may have the opportunity to receive the same or a similar experimental drug at a later date, resulting in unplanned cross-over and ultimately impacting the OS results from the original study [34] . The effect of cross-over on outcomes warrants consideration in the initial trial design and statistical calculations. Planned cross-over should be considered in patient cohorts with an expected long median OS (for example >3 years) as it may avoid informative censoring.
Progression-free survival (PFS) is not affected by these factors, but it remains controversial whether this truly reflects patient benefit [34] . It was recommended that PFS should not be viewed as an acceptable endpoint alone in ROC but should be supported by additional evidence of clinical benefit. This was accepted by all member groups except one. This minority view reflected that the FDA recently stated that a PFS benefit of a 'substantial magnitude' could be viewed as evidence of effect [35] .
It was agreed that endpoints may differ according to the expected median OS of the population selected. In trials where the expected median OS is < or ¼12 months, OS is the preferred endpoint as post-progression survival is short [29] . PFS could represent a reasonable alternative endpoint for OS but should be supported by additional measures of clinical benefit such as time until definitive deterioration of quality of life (TUDD) and PROs. It is still critical to demonstrate improvement in quality of life even if there is an apparent OS benefit. When interpreting trial results, it is important to ensure the study was appropriately powered to allow interpretation of secondary endpoints and that the PRO analyses were pre-defined and included in the statistical analysis plan.
In patients where a median OS of >12 months is expected, PFS supported by additional measures of clinical benefit, such as time to second subsequent therapy or death (TSST) and/or PROs, is the preferred endpoint. TSST may be more reliable than PFS2 (time to second progression) as it is easier to measure than PFS2, which is reliant on systematic radiological assessment after disease progression, whilst TSST reflects the time until patients require further treatment [9, 36] . Arguably this is also more clinically meaningful. Nonetheless, there may be bias due to patient heterogeneity and the varying reasons for treatment decisions post-progression [34] . Whilst these endpoints are new, the European Medicines Agency has recognised PFS2 as a relevant endpoint in this patient population [37] .
PROs are reported by the patients themselves to give better insight into the patient's experience of treatment and particularly toxicity beyond the CTCAE (common terminology criteria for adverse events) grading [38, 39] . Context-specific PROs are needed which support the study objectives, with integration of appropriate instruments to reflect this. Reporting quality of life endpoints requires stringent control similar to that of RECIST (response evaluation criteria in solid tumours) [34] . In order to define (or exclude) benefit, trials need to include a pre-defined PRO hypothesis and statistical analysis plan and ensure appropriate timing and duration of measurements (typically until TSST). Missing data are an issue in the interpretation of PROs, and strategies to address this issue are critical.
Assessment of the TUDD of quality of life can support the PFS endpoint in trials of palliative chemotherapy. Reporting the time until a 10 point and 20 point deterioration overall, as well as in individual domains of quality of life, has been used to successfully demonstrate benefit in other advanced cancers such as pancreatic cancer [40] . 1. In patients where platinum is not an option, a control arm can include a non-platinum drug as a single agent or in combination. 2. The choice of control arms for the subgroup of patients who can receive platinum must be supported by evidence and it must integrate available predictors and prior exposure, which may limit selection for further lines. This currently includes three potential control arms: Platinum combination Platinum combination with a licensed anti-angiogenic agent Platinum combination followed by a licensed PARP inhibitor 3. There is a subgroup (e.g. medically compromised and/or elderly patients) where less toxic therapy or best supportive care may be the most appropriate control arm. 4. There is no proven effective therapy for patients who have asymptomatic CA-125 relapse.
The choice of the tool with which to assess PROs is important. The new PRO measure developed by the GCIG symptom benefit committee-Measure of Ovarian Symptoms and Treatment (MOST)-has the potential to be widely used in clinical trials and is currently undergoing validation [41] .
Unmet needs
As discussed, trials in the elderly and medically unfit represent two cohorts where more research is needed. Additionally, patients who have received multiple lines of therapy should not be excluded from clinical trials but would benefit from trials designed for this heavily pre-treated patient population. The question was also raised as to whether a control arm is necessary in selected populations where patient outcomes are particularly poor such as in patients with progression during chemotherapy.
Clinical trials in patients with an asymptomatic CA-125 progression remain an area of interest. Well-designed trials of targeted therapies or immune checkpoint blockade in patients with a low tumour burden are under consideration.
It is important to recognise the increasing cost of clinical trials, of both a monetary and non-monetary nature. The frequency of radiological assessments in trials often exceeds that of standard of care and exacerbates the increasing financial costs of drug development. Financial toxicity, the burden of 'out-of-pocket' expenses, has been described as an additional toxicity to therapy [42] . As trials are carried out in a resource poor environment, these aspects need consideration.
Conclusion
It is time to challenge clinical trial design and criteria for patient selection in ROC and move from the classic paradigm of platinum-sensitive and resistant disease to integrate a more informative TFI stratification. This, in conjunction with other patient and tumour-related factors including predictive biomarkers, are important considerations in trial design. Endpoints need to reflect the disease and agent in question and focus not only on the quantity of life but also the quality of life. In an era of limited resources, it is important to consider rationalising the number of investigations in trials to mirror clinical practice. The GCIG is well positioned to lead these changes.
